Alamar Biosciences
Alamar is seeking a Scientist I in Technology Development to join its team in Fremont, California, focusing on the development of a novel protein detection platform. The role involves designing and executing experiments for multiplex biomarker assays, generating high-quality data, and supporting the integration of assay workflows onto proprietary instruments. This position requires a strong background in assay development, molecular biology, and data analysis to translate innovative technologies into robust products.
Headquarters
Fremont, California, United States
Company Size
51-200 employees
Founded
2018
Alamar Biosciences is a proteomics-focused biotech company developing a next-generation proteomic platform with ultra-high sensitivity and multiplexing for plasma protein detection and liquid biopsies. Their technology is designed to detect low-abundance protein biomarkers with high precision, supporting biomarker discovery, disease monitoring, and translational/clinical diagnostics. Alamar positions its platform as enabling more sensitive, multiplexed protein measurements for research and clinical applications.
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Jan 11, 2026
Alamar Biosciences Expands Executive Leadership to Power Next Phase of Growth
Oct 15, 2025
Global Alzheimer’s Platform Foundation Announces Strategic
Jan 9, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Alamar Biosciences.
Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research
Jan 12, 2026